Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)

May combine two claims.

A phase 2 trial of BMS-986278 (admilparant) in 278 IPF patients showed a 62% relative reduction in the rate of change of percent predicted FVC in the 60 mg group versus placebo, with no significant difference in the 30 mg group.

“A phase 2 trial (NCT04308681) comparing placebo versus 30 mg versus 60 mg in a 1:1:1 distribution of a new LPA1 antagonist BMS-986278 or Admilparant in 278 patients with IPF diagnosed within seven years demonstrated a 62% relative reduction in rate of change of percent predicted FVC (95% CI 0.2 – 3.4) in the 60 mg group in comparison to placebo and no significant difference in the 30 mg group when”

• cites [94] sourceDisputed

  The Methods and Patients sections describe a different trial: 326 patients with interstitial lung disease and pulmonary hypertension were assigned to inhaled treprostinil or placebo. Its primary endpoint was six-minute walk distance, not percent-predicted FVC. The cited paper therefore contradicts the claim’s identification of its drug, trial population, treatment groups, and endpoint; it does not report the claimed BMS-986278 result. Page numbers were not available for these passages. (LLM, conf=0.90)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [97] sourceCould not verify

  The References (p. 19) cite a paper on the design of a BMS-986278 phase 2 trial, but our copy does not report that trial’s results. The Study Design section (p. 5) and Primary Outcome section (p. 11) instead describe phase 3 trials of ziritaxestat. Searches for BMS-986278, admilparant, the 62% reduction, and NCT04308681 found no passage supporting the claimed result. (LLM, conf=0.77)

  Experimental — accuracy not yet measured
• cites [98] sourceNot checked — no full text of the source

May combine two claims.

Pirfenidone and nintedanib are approved for IPF and both reduce the rate of lung function decline.

“Currently, two agents, pirfenidone and nintedanib are approved for this disease and both have been shown to reduce the rate of decline in lung function in patients with IPF.”

• cites [9] sourceNot checked — no full text of the source
• cites [10] sourceNot checked — no full text of the source
• cites [11] sourcePartly supported

  In Part II, under the nintedanib Background (page unavailable), the guideline says that nintedanib, like pirfenidone, slows disease progression in IPF. The Introduction describes antifibrotic therapies as accepted for IPF, but the passages do not establish that both agents are formally approved for it. The treatment-effect claim is supported; the approval claim is not verified by this copy. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Idiopathic pulmonary fibrosis is a progressive fibrosing lung disease with median survival under five years.

“Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing lung disease with a median survival of less than 5 years.”

• Also stated in: § Introduction · hedged

  “It is a progressive disease leading to respiratory failure with a historical median survival of 3–5 years from diagnosis [5][6].”

• cites [5] sourceNot checked — no full text of the source
• cites [6] sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

IPF is diagnosed only after other causes of fibrosing interstitial lung disease are excluded, but it has known environmental and genetic risk factors.

“IPF is considered idiopathic and can only be diagnosed when other causes of fibrosing interstitial lung disease (ILD) have been eliminated; however, it has many known environmental and genetic risk factors [2–4].”

• cites [2] sourceNot checked — no full text of the source
• cites [3] sourcePartly supported

  The Introduction states that genetic and environmental factors contribute to IPF risk, and the paper discusses specific genetic variants. Our copy does not state that IPF can be diagnosed only after other causes of fibrosing ILD have been excluded; searches for that diagnostic requirement found no supporting passage. No page number was available for the indexed passages. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [4] sourceSupported

May combine two claims.

International guidelines recommend only nintedanib and pirfenidone for IPF, and both are conditionally recommended with moderate confidence in effect estimates.

“there remain only two pharmacologic treatments recommended for use – nintedanib and pirfenidone [9–11]. Additionally, both of these medications are only conditionally recommended based on moderate confidence in effect estimates”

• cites [9] sourceNot checked — no full text of the source
• cites [10] sourceNot checked — no full text of the source
• cites [11] sourcePartly supported

  In Part II, under the pirfenidone and nintedanib Background sections (page not supplied), the guideline says prior guidelines recommended both drugs for IPF. Our copy does not establish that they are the only recommended pharmacologic treatments for IPF or that both IPF recommendations were conditional with moderate confidence in effect estimates. Its conditional nintedanib recommendation concerns non-IPF PPF and is based on low-quality evidence, so it cannot substantiate those IPF-specific details. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

Pirfenidone and nintedanib have significant adverse effects and neither completely stops lung function decline.

“However, both have significant adverse effects and neither completely arrest the decline in lung function.”

• Also stated in: § Introduction · plain

  “neither completely stop the progression of pulmonary fibrosis [9,10]”

• cites [9] sourceNot checked — no full text of the source
• cites [10] sourceNot checked — no full text of the source
• cites [12] sourceNot checked — no full text of the source
• cites [13] sourceNot checked — no full text of the source
• cites [14] sourcePartly supported

  The Results and Conclusions text in passage [3] reports that nintedanib slowed, but did not stop, FVC decline and was frequently associated with diarrhea. It does not report pirfenidone’s adverse effects or its effect on lung-function decline, so it supports only the nintedanib portion of the claim. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [15] sourceNot checked — no full text of the source

May combine two claims.

PANTHER-IPF found increased hospitalizations and death in the triple therapy arm compared with placebo, with no physiological or clinical benefit.

“PANTHER-IPF, compared this three-drug combination (acetylcysteine, prednisone, and azathioprine) to acetylcysteine alone and placebo and found an increased rate of hospitalizations and death (P=0.01) in the triple therapy arm compared to placebo [62]. No physiological or clinical benefit was found in the triple therapy group”

• cites [62] sourceCould not verify

  The study design (p. 3) compares acetylcysteine with its placebo while all patients receive prednisone and azathioprine; it does not describe the three-arm PANTHER-IPF comparison. The discussion (p. 13) says the trial had no placebo group for prednisone and azathioprine and was not designed to detect a survival effect. Searches for PANTHER-IPF, hospitalizations, and the claimed three-arm outcomes found no passage addressing those findings. (LLM, conf=0.79)

  Experimental — accuracy not yet measured

May combine two claims.

In the ATLAS trial, inhaled pirfenidone was safe, with FVC percent predicted changes of -2.5 and -4.9 at 24 and 48 weeks for 50 mg once daily, and 0.6 and -0.4 for 100 mg twice daily.

“Results of the ATLAS trial demonstrated that inhaled pirfenidone was safe to use, with changes in FVC % predicted of −2.5 (95% CI −5.3 to 0.4, −88 mL) and −4.9 (−7.5 to −2.3,–188 mL) at 24 and 48 weeks, respectively, in the 50 mg once per day and 0.6 (−2.2 to 3.4, 10 mL) and −0.4”

• cites [39] sourceCould not verify

  The Pirfenidone section discusses clinical trials and adverse effects generally, but does not mention the ATLAS trial or inhaled pirfenidone. Searches for the ATLAS dosing regimens and the stated FVC changes found no passage reporting those results; the References section likewise does not resolve the claim. (LLM, conf=0.73)

  Experimental — accuracy not yet measured

May combine two claims.

Nintedanib is an oral tyrosine kinase inhibitor that inhibits PDGF receptors alpha/beta, VEGF receptors 1-3, FGF receptors 1-3, and potentiates SHP-1.

“Nintedanib has inhibitory effects on platelet-derived growth factor receptors α/β (PDGFα/β), vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, and fibroblast growth factor (FGF) receptor 1, 2, and 3, as well as potentiation of Src homology region 2 domain containing phosphatase 1 (SHP-1) [19,20].”

• cites [19] sourcePartly supported

  The Summary and conclusion describes nintedanib as an orally active tyrosine kinase inhibitor, and the section on PDGFR, FGFR and VEGFR inhibition lists the claimed receptor targets. Our copy does not report potentiation of SHP-1; its discussion of Src concerns inhibition of Src-family kinases, which is a different claim. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [20] sourcePartly supported

  The Introduction identifies nintedanib as an inhibitor of PDGFR, VEGFR and FGFR, and the Results (‘Nintedanib targets SHP-1 in TNBC cells’) report that it potentiates SHP-1 activity. Our copy does not specify the receptor subtypes listed in the claim or describe nintedanib as oral. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

May combine two claims.

Diarrhea is the most common adverse event with nintedanib and is usually mild to moderate; nausea is more frequent than with placebo, and nintedanib has more adverse events leading to discontinuation than placebo.

“Diarrhea was the most common AE with most reporting this AE as a mild to moderate intensity [14]. In addition, nausea was more frequently reported with nintedanib than placebo and nintedanib had greater overall AE’s leading to treatment discontinuation than placebo [14].”

• cites [14] sourceCould not verify

  The indexed passages contain a repository record and an abstract, but no full-text results or safety section. Searches for diarrhea severity, nausea, and adverse events leading to discontinuation returned no eligible full-text passage, so the complete claim cannot be verified from our copy. (LLM, conf=0.72)

  Experimental — accuracy not yet measured

May combine two claims.

In CLEANUP-PF, there was no difference in FVC between the two antifibrotic groups at month 24 and no difference in hospitalizations or death.

“However, there was no difference in FVC between two antifibrotic groups at month 24. Similarly, no difference in hospitalizations or death was found between the two groups.”

• cites [50] sourceCould not verify

  The Methods and Results compare patients by how long before transplant they stopped antifibrotic medication, with outcomes reported through six months after transplant. Although the Post-discharge outcomes section reports no survival difference between those timing groups, our copy does not report a CLEANUP-PF comparison of the two drugs for FVC at month 24, hospitalizations, or death. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

A post-hoc analysis of INCREASE found no significant between-group difference in absolute FVC change at week 16; however, FVC percent predicted rose by 1.8% (95% CI 0.4-3.2) at 8 weeks and by 1.8% (95% CI 0.2-3.4) at 16 weeks.

“Post-hoc analysis demonstrated no statistically significant difference in change in absolute FVC at week 16 (a secondary safety end point); however, FVC percent predicted improved by 1.8% (95% CI 0.4 to 3.2) at 8 weeks and 1.8% (95% CI 0.2 to 3.4) at 16 weeks [122].”

• cites [122] sourceCould not verify

  The Discussion describes PDE4-subtype effects on human lung fibroblast proliferation and myofibroblast conversion, not outcomes from the INCREASE trial. Searches for INCREASE, FVC, the 8- and 16-week results, and the reported confidence intervals found no passage addressing the claim in our copy. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

The ATX-LPA-LPA receptor axis plays a role in the pathogenesis of IPF and can decrease the severity of bleomycin-induced pulmonary fibrosis in mouse models.

“This ATX – LPA – LPA receptor axis has been found to play a role in the pathogenesis of IPF, and can decrease severity of bleomycin induced pulmonary fibrosis in mouse models [100].”

• cites [100] sourceCould not verify

  The Introduction (page not provided) discusses MMP-7, osteopontin and FasL as IPF biomarkers, but does not address the ATX–LPA–LPA receptor axis. Searches of our untruncated copy for that axis, autotaxin and lysophosphatidic acid, and bleomycin-induced fibrosis in mice found no passage supporting the claim. (LLM, conf=0.77)

  Experimental — accuracy not yet measured

• AssumptionRests on an assumption: Findings from bleomycin-induced fibrosis in animal models are predictive of clinical efficacy in human IPF.

May combine two claims.

In rats pretreated with intratracheal silencing of MMP7 mRNA, bleomycin-induced fibrosis was reduced, with improved lung function and reduced fibrosis compared with control.

“In rats pretreated with intratracheal silencing MMP7 mRNA, bleomycin induced fibrosis (through the mechanism of MMP7 overexpression) was reduced, leading to improved lung function with reduced fibrosis compared to control [91].”

• cites [91] sourceCould not verify

  The Discussion reports antifibrotic effects of bexotegrast in murine models and reduced FVC decline in patients with IPF, but it does not describe MMP7 silencing in rats. Searches for intratracheal MMP7 mRNA silencing and MMP7 knockdown with bleomycin found no passage addressing the claimed experiment. Page numbers were not available in our copy. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

• AssumptionRests on an assumption: Findings from bleomycin-induced fibrosis in animal models are predictive of clinical efficacy in human IPF.

May combine two claims.

PDE4A, B, and D are expressed in human lung fibroblasts, and PDE4B knockdown inhibits basic FGF, IL-1beta, and TGF-beta and decreases differentiation into myofibroblasts.

“PDE4A, B and D are expressed in human lung fibroblasts, with PDE4B knockdown leading to inhibition of cytokines basic FGF and IL-1β and TGF-β and subsequent decreased differentiation into myofibroblasts [113,114].”

• cites [113]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [114] sourceCould not verify

  The Background and Results passages discuss αv-integrin inhibition and TGF-β signaling in lung tissue, not PDE4 expression or knockdown. Searches for PDE4B knockdown, basic FGF, IL-1β, and fibroblast differentiation found no passage addressing the attributed claim. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

• AssumptionRests on an assumption: In vitro effects on human lung fibroblasts or precision-cut lung slices are predictive of clinical benefit in IPF.

May combine two claims.

The INJOURNEY open-label randomized controlled trial in 111 IPF patients found a suggestion of further reduction in FVC decline with nintedanib plus pirfenidone at 12 weeks, with little change in nintedanib plasma trough levels.

“The INJOURNEY trial was an open-labelled, RCT of 111 IPF patients treated with nintedanib with or without pirfenidone [84]. When the combination therapy went 12 weeks, a suggestion of a further reduction in FVC decline was seen. Little change in nintedanib plasma trough levels were found.”

• cites [84] sourceCould not verify

  The Results (Patient population and disposition; Efficacy, pages unavailable) describe this paper’s seven-patient trial with a six-month endpoint, not the claimed 111-patient, 12-week INJOURNEY trial. The References name an INJOURNEY paper, but our copy does not report its patient count, 12-week FVC finding, or nintedanib plasma trough levels (searched: INJOURNEY, 111, 12 weeks, plasma trough levels). (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

IPF patient lungs contain more activated JNK, and this increase tracks with fibrosis severity.

“Lungs of patients with IPF have increased level of activated JNK, which do correspond to severity of fibrosis [141–144].”

• cites [141] sourceCould not verify

  The Results > Potential Therapeutic Targets passage discusses MAP3K5 in ALS CNS tissue, not activated JNK in lungs of patients with IPF. Searches for IPF, activated JNK, and fibrosis severity found no passage in our copy addressing the claimed increase or its relationship to severity (page numbers unavailable). (LLM, conf=0.77)

  Experimental — accuracy not yet measured
• cites [142] sourceCould not verify

  The section on CDK20 as a promising target for cancer treatment (page unavailable) discusses lung cancer cells, not lungs of patients with IPF. Searches for activated JNK, IPF, and fibrosis severity found no passage addressing the claimed increase or its relationship to severity. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [143] sourceCould not verify

  The Results section on AI-discovered anti-fibrotic targets names JNK signaling among pathways associated with fibrosis, but does not report activated JNK levels in IPF patient lungs or a relationship with fibrosis severity. Searches for activated or phosphorylated JNK and disease severity found no passage addressing those measurements. Page numbers were not available in our copy. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [144] sourceCould not verify

  Section 4 discusses fibrosis in IPF and activation of Hedgehog signaling, but does not report increased activated JNK in patient lungs or a relationship between JNK activation and fibrosis severity. Searches for “activated JNK severity of fibrosis,” “c-Jun N-terminal kinase phosphorylation IPF severity,” and “JNK” found no passage addressing either point. (LLM, conf=0.72)

  Experimental — accuracy not yet measured

May combine two claims.

Factor XIIa-β raises bradykinin activity and stimulates lung fibroblasts to produce IL-6.

“While Factor XIIa-β does increase bradykinin activity, it also promotes IL-6 production from lung fibroblasts [165,166].”

• cites [165] sourceNot checked — no full text of the source
• cites [166] sourceCould not verify

  The Results and Discussion passages concern the AETHER mesenchymal-stem-cell safety trial, while the References passage mentions lung fibroblasts only in connection with other mechanisms. Searches for Factor XIIa-β, bradykinin, and IL-6 production by lung fibroblasts found no passage in our copy addressing the claim. (LLM, conf=0.77)

  Experimental — accuracy not yet measured

May combine two claims.

In a phase 1 trial, bersiposocin caused gastrointestinal adverse events related to treatment, but no serious adverse events occurred.

“A phase 1 trial (ACTRN12619001239156) was completed and demonstrated treatment-related GI adverse events, but no serious adverse events were reported [125].”

• cites [125] sourceCould not verify

  The Methods (Animals and Experimental design; pages unavailable) describe a mouse study of treprostinil, not a phase 1 trial of bersiposocin. Searches for bersiposocin, trial identifier ACTRN12619001239156, gastrointestinal adverse events, and serious adverse events found no passage addressing the claimed trial outcomes. (LLM, conf=0.77)

  Experimental — accuracy not yet measured

May combine two claims.

Cellular stress raises JNK, which drives inflammatory gene expression and starts the fibrotic process.

“JNK is increased in cellular stress and leads to inflammatory gene expression and start of the fibrotic process [141–144].”

• cites [141] sourceCould not verify

  The Results sections discuss stress-response pathways and inflammation in ALS, but do not say that cellular stress increases JNK or that JNK drives inflammatory gene expression and initiates fibrosis. Searches for the stated JNK mechanism and for JNK with fibrosis and inflammation found no supporting passage in our copy; the passages have no page numbers. (LLM, conf=0.74)

  Experimental — accuracy not yet measured
• cites [142] sourceCould not verify

  The section “CDK20 as a promising target for cancer treatment” (page unavailable) discusses CDK20, reactive oxygen species and tumor immunosuppression, but not the claimed JNK pathway. Searches for JNK, c-Jun N-terminal kinase, and fibrotic process found no passage linking cellular stress to JNK, inflammatory gene expression and fibrosis. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [143] sourceCould not verify

  The Discussion (page unavailable) says TNIK belongs to kinases that activate a profibrotic c-JUN pathway, and the References list a study of stress-induced JNK signaling. The paper’s Results discuss other inflammatory and fibrotic signaling pathways, but the passages found do not say that cellular stress increases JNK or that JNK induces inflammatory gene expression and initiates fibrosis. Searched for JNK, cellular stress, and inflammatory gene expression. (LLM, conf=0.72)

  Experimental — accuracy not yet measured
• cites [144] sourceCould not verify

  Section 4.2 discusses Hedgehog signaling, inflammation, and fibrosis, but does not link them through JNK. Searches for JNK and for cellular stress leading to inflammatory gene expression found no passage in our copy addressing the claimed sequence. (LLM, conf=0.70)

  Experimental — accuracy not yet measured

May combine two claims.

Preclinical work found prostaglandins protect against fibrosis in bleomycin-induced lung injury, whereas platelet-derived thromboxane A2 causes platelet aggregation and smooth muscle contraction.

“Preclinical research showed prostaglandins are protective against fibrosis in bleomycin induced lung injury, and platelet produced thromboxane A2 (TXA2) leads to platelet aggregation and smooth muscle contraction [167].”

• cites [167] sourceCould not verify

  The Discussion (page unavailable) describes experimental attenuation of lung fibrosis by stem-cell therapy, not by prostaglandins. Searches of our copy for prostaglandins, thromboxane A2/TXA2, platelet aggregation, and smooth-muscle contraction found no passage addressing the attributed claims. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

AIR secondary endpoints included a 57% decrease in plasma TGF-β1 (from 21.3 ± 5 to 7.1 ± 1.5 ng/mL) and a 67% increase in MMP-13 (P=0.01) relative to baseline.

“Important secondary endpoints included reduction of plasma levels of TGF-β1 by 57% (21.3 ± 5 to 7.1 ± 1.5 ng/mL) and elevation in matrix metalloproteinase 13 (MMP-13) levels by 67% (P=0.01) compared to baseline [129].”

• cites [129] sourceCould not verify

  The Results section on the TGF-β pathway reports SMAD2 phosphorylation in treated cells, not a change in plasma TGF-β1. The Materials and Methods section on blood testing lists mouse hematology and serum chemistry measurements, but not MMP-13. Searches for the stated values, percentages, MMP-13, and secondary endpoints found no passage reporting the claimed changes. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

In the phase 2 AIR trial, 46 treatment-naive IPF patients received placebo or buloxibutid 100 mg twice daily; the change from baseline in FVC was −50 mL (90% CI −150 to +50) at 24 weeks and +13 mL (90% CI −69 to +96), normalized, at 36 weeks.

“The AIR study is a phase 2 trial (NCT04533022) of 46 patients with treatment naïve IPF who were given placebo or buloxibutid 100 mg twice daily with results demonstrating a change from baseline in FVC of −50 mL (90% CI −150, +50) at 24 weeks and +13 mL (90% CI −69, +96), normalized, at 36 weeks [129].”

• cites [129] sourceCould not verify

  Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

Bersiposocin (DWN12088) inhibits PARS1, lowering collagen synthesis, and is therefore a possible target in pulmonary fibrosis, where excess collagen deposition is a key pathological feature.

“Bersiposocin (DWN12088) is a PARS1 inhibitor, which leads to downregulation of collagen synthesis, and thus is a potential therapeutic target in pulmonary fibrosis where excessive collagen deposition is a major pathological feature [124].”

• cites [124] sourcePartly supported

  The Introduction describes aberrant collagen type-I deposition in idiopathic pulmonary fibrosis, and the Discussion identifies collagen deposition as a contributor to fibrosis. But the paper studies treprostinil through cAMP activation; it does not identify bersiposocin (DWN12088) as a PARS1 inhibitor or support the claimed effect of that drug on collagen synthesis. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

In vitro work showed that siRNA TRK-250 suppressed TGF-β1 expression and lowered TGF-β1 mRNA, suggesting a possible therapeutic effect in IPF.

“In vitro studies demonstrated inhibited TGF-β1 expression and reduced levels TGF-β1 mRNA levels after treatment with siRNA TRK-250, suggesting a potential therapeutic effect in IPF.[152].”

• cites [152] sourcePartly supported

  The Results and Discussion report reduced TGF-β1 mRNA in rat lungs after treatment with compound 1, a dual ROCK inhibitor. The paper’s in vitro results concern other mRNA markers, not TGF-β1, and the cited passages do not report treatment with siRNA TRK-250. Thus the reduction in TGF-β1 mRNA is supported, but the claimed treatment and in vitro setting are not. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Belumosudil (KD025) inhibits ROCK2 and modulates fibrosis through several routes: it increases pulmonary microvascular endothelial cell necrosis under hypoxia, strengthens the pulmonary endothelial barrier, and raises oxidative phosphorylation while inhibiting glycolysis in those cells.

“Belumosudil, or KD025 is a ρ-associated coiled-coil kinase isoform 2 (ROCK2) inhibitor with several pathways of fibrotic modulation: increases pulmonary microvascular endothelial cell necrosis in hypoxia, strengthens the integrity of the pulmonary endothelial barrier, and increases oxidative phosphorylation and inhibits glycolysis in pulmonary microvascular endothelial cells [146–148].”

• cites [146] sourceNot checked — no full text of the source
• cites [147] sourceCould not verify

  Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured
• cites [148] sourceNot checked — no full text of the source

May combine two claims.

Because elevated MMP-13 has been linked to several cancers, there is concern that buloxibutid may carry malignant potential.

“There is some concern regarding the malignant potential of buloxibutid given the association of increased MMP-13 levels in several cancers [130–134].”

• cites [130] sourceCould not verify

  The Abstract and Discussion concern bersiporocin and collagen biomarkers, not buloxibutid or malignant potential. Searches for buloxibutid, MMP-13, and cancer found no passage in our copy linking elevated MMP-13 to cancers or to a risk from buloxibutid; the References mention other MMP-related work, but not that claim. (LLM, conf=0.78)

  Experimental — accuracy not yet measured
• cites [131] sourceCould not verify

  The Results (p. 12) discuss angiotensin II–induced proliferation of pulmonary artery smooth muscle cells, not cancer or buloxibutid. Searches for buloxibutid, MMP-13, matrix metalloproteinase 13, and malignancy found no passage in our copy addressing the claimed link or malignant potential. (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [132] sourceNot checked — no full text of the source
• cites [133] sourceCould not verify

  The Results and Discussion (pages unavailable) discuss C21’s effects on Mmp12 in a bleomycin-induced lung-injury model, not MMP-13. Searches for MMP-13, cancer, and malignant potential found no passage linking elevated MMP-13 to cancers or raising a malignancy concern about C21. (LLM, conf=0.77)

  Experimental — accuracy not yet measured
• cites [134]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

ND L02-s0201 is a lipid nanoparticle carrying siRNA that inhibits HSP47, a collagen-specific chaperone needed for proper collagen formation.

“ND L02-s0201 (formerly BMS 986263) is a lipid nanoparticle containing siRNA which inhibits HSP47, which is a collagen specific chaperone that ensures proper collagen formation [190].”

• cites [190] sourceCould not verify

  Section 7.3 discusses HSP90 as a molecular chaperone and potential pulmonary-fibrosis target, but does not address HSP47. Searches for ND L02-s0201, BMS 986263, lipid-nanoparticle siRNA, and HSP47’s role in collagen formation found no passage supporting the claim in our copy; no page number was provided. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

TTI-101 (C188-9), a small-molecule STAT-3 inhibitor, reduced HIF-1α and PAI-1 and subsequently decreased fibroblast-to-myofibroblast transition.

“TTI-101 (C188–9) is a small molecule inhibitor of STAT-3, which led to decreased hypoxia-inducible factor −1α (HIF-1α) and plasminogen activator inhibitor-1 (PAI-1), which are both markers of epithelial injury [177]. Subsequent decrease in fibroblast to myofibroblast was also seen [177].”

• cites [177] sourceCould not verify

  The Discussion discusses possible effects of blocking the oncostatin M pathway on skin fibrosis, but not TTI-101 or STAT-3 inhibition. Searches for TTI-101, C188-9, HIF-1α, PAI-1, and fibroblast-to-myofibroblast transition found no passage addressing the attributed findings. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

A phase 2 trial of ND L02-s0201 showed safety but no efficacy in the treatment arm.

“A phase 2 trial was conducted (NCT03538301) with results demonstrating safety but no efficacy in the treatment arm [192].”

• cites [192] sourceCould not verify

  The Methods and Results (p. 3) describe cell-based experiments on TGF-β and Smurf2, not a clinical trial. Searches for ND L02-s0201, NCT03538301, and trial safety or efficacy found no passage addressing the claimed phase 2 results. (LLM, conf=0.78)

  Experimental — accuracy not yet measured

May combine two claims.

SMURF1 and SMURF2 drive ubiquitin-dependent Smad7 degradation and enhance TGF-β, contributing to pulmonary fibrosis.

“SMURF1 and SMURF2 promote ubiquitin-dependent degradation of Smad7 and enhancement of TGF-β, which contributes to pulmonary fibrosis [186].”

• cites [186] sourceCould not verify

  The Background and Discussion discuss MMP/TIMP imbalance in pulmonary fibrosis and mention active TGF-β gene transfer, but neither addresses SMURF1, SMURF2, Smad7, or ubiquitin-dependent degradation. Searches for those terms and their proposed connection to TGF-β found no passage supporting the attributed mechanism; page numbers were unavailable in our copy. (LLM, conf=0.76)

  Experimental — accuracy not yet measured

May combine two claims.

Phosphorylated STAT-3 is increased in IPF patient biopsies and in mice with bleomycin-induced pulmonary fibrosis.

“STAT is a downstream signaling molecule from JAK activation with seven subtypes: phosphorylated STAT-3 is elevated in biopsies of patients with IPF and in mice with bleomycin induced pulmonary fibrosis. [174–177]”

• cites [174] sourceCould not verify

  The Oncostatin M signaling section (page unavailable) describes STAT3 activation downstream of JAK, but does not report phosphorylated STAT3 levels in IPF biopsies. The Activation of the inflammatory cells section reports increased OSM and LIF mRNA in bleomycin-induced lung fibrosis, not increased phosphorylated STAT3. Searches for IPF biopsies and STAT3 phosphorylation found no passage establishing either claimed observation. (LLM, conf=0.74)

  Experimental — accuracy not yet measured
• cites [175] sourceNot checked — no full text of the source
• cites [176] sourceNot checked — no full text of the source
• cites [177] sourceCould not verify

  The Discussion (page unavailable) mentions the OSM pathway in fibrosis and a possible effect on skin fibrosis, but does not address phosphorylated STAT-3 in IPF biopsies or bleomycin-treated mice. Searches for those terms and for JAK/STAT signaling found no passage supporting the attributed claim. (LLM, conf=0.77)

  Experimental — accuracy not yet measured

May combine two claims.

Pirfenidone is an oral agent with unknown exact mechanism, proposed to act through antioxidant, anti-inflammatory, and antifibrotic effects involving TNF-alpha, TGF-beta1, and the p38 pathway.

“pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), an oral agent whose exact mechanism of action is unknown but is proposed to have antioxidant, anti-inflammatory and antifibrotic actions perhaps by its antagonism of the effects of tumor necrosis factor α (TNF-α), transforming growth factor β1 (TGFβ1) and interference in the p38 profibrotic pathway [16,17].”

• cites [16] sourceNot checked — no full text of the source
• cites [17] sourceNot checked — no full text of the source

May combine two claims.

In three trials using doses up to 2403 mg/day, pirfenidone reduced FVC decline but had variable effects on overall and IPF-related mortality.

“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”

• cites [12] sourceNot checked — no full text of the source
• cites [13] sourceNot checked — no full text of the source

May combine two claims.

Sodium pyruvate nasal spray reduces reactive oxygen species in airway epithelium by increasing glutathione levels, and a small study of 15 patients with pulmonary fibrosis and COPD or pulmonary fibrosis alone showed clinically significant improvement in FEV1/FVC ratio from 52% to 86%, decreased coughing, increased expelled nitric oxide, and improved nasal irritation and erythema.

“By increasing glutathione levels, sodium pyruvate nasal spray, does reduce ROS in the airway epithelium [112]. A small study of 15 patients with either pulmonary fibrosis and COPD or pulmonary fibrosis alone received sodium pyruvate nasal spray and had baseline FEV1, FVC, peak expiratory flow (PEF), FEV1/FVC ratios, peripheral oxygen saturation, exhaled nitric oxide levels, coughing rates, and”

• cites [112] sourceNot checked — no full text of the source

May combine two claims.

Bexotegrast is a small molecule dual inhibitor of alpha-v-beta-6 and alpha-v-beta-1, and cumulative phase 1/2 data in 630 patients showed mild adverse effects, with diarrhea most common in phase 2.

“Bexotegrast is a small molecule dual inhibitor of αvβ6 and αvβ1[105]. Cumulative data of 630 patients composed of several phase 1 and 2 trials investigating αvβ6 and αvβ1 in both IPF and primary sclerosing cholangitis demonstrated mild adverse effects in the bexotegrast group (headache, diarrhea, and nausea), with diarrhea being the most common in phase 2 studies”

• cites [104] sourceNot checked — no full text of the source
• cites [105] sourceNot checked — no full text of the source

May combine two claims.

MMP7 is overexpressed by basaloid cells and is a validated marker of disease severity and progression in IPF.

“MMP7 is overexpressed by basaloid cells and has become a validated marker of disease severity and progression in IPF [89,90].”

• cites [89] sourceNot checked — no full text of the source
• cites [90] sourceNot checked — no full text of the source

May combine two claims.

A meta-analysis covering 2124 patients, 1274 of whom received pulmonary hypertension-specific drugs, found only modest quality-of-life gains in PH-IPF, which the authors say is insufficient to justify broad use.

“A systematic review and meta-analysis of 2124 patients, with 1274 on pulmonary hypertension specific agents demonstrated only small quality of life benefits in patients with PH and IPF, thus there is insufficient evidence to support their widespread use [119].”

• cites [119] sourceNot checked — no full text of the source

May combine two claims.

A meta-analysis of four trials in 191 IPF patients treated with pirfenidone plus nintedanib found gastrointestinal symptoms were the most common adverse event, and about 29% stopped the trials with high serious and any adverse event rates.

“Lee and colleagues did a meta-analysis on four clinical trials that included 191 IPF patients treated with a combination of pirfenidone and nintedanib [85]. Gastrointestinal symptoms were the most common adverse event reported. About 29% of the combination treated patients stopped the trials with a high serious and any adverse event rates noted.”

• cites [85] sourceNot checked — no full text of the source

May combine two claims.

REBUILD, a phase III trial of pulsed inhaled nitric oxide in IPF patients receiving supplemental oxygen and considered at risk for pulmonary hypertension, failed its primary 6MWD endpoint and was stopped for futility.

“The REBUILD study (NCT03267108) was a phase III RCT investigating pulsed inhaled nitric oxide in patients with IPF on supplemental oxygen at baseline who were deemed to be at risk for pulmonary hypertension. The primary end point of change in 6MWD was ultimately not met, and thus the study was terminated due to futility.”

• cites NCT03267108Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

A phase 2 trial with open-label extension of zinpentraxin showed no significant difference in serious adverse events versus placebo, with a significant decrease in FVC percent predicted and stabilization of 6MWD.

“A phase 2 trial with its open label extension (NCT02550873) demonstrated no significant difference in serious AEs (SAE) in the treatment arm from placebo, with a significant decrease in FVC percent predicted and stabilization of the 6MWD.”

• cites NCT02550873Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

Axatilimab is a humanized IgG4 monoclonal antibody with high affinity for CSF-1R.

“Mainly studied for its role in chronic graft versus host disease, axatilimab is a high affinity humanized IgG4 monoclonal antibody targeting colony stimulating factor 1 receptor (CSF-1R) [123].”

• cites [123] sourceNot checked — no full text of the source

May combine two claims.

In animal models, prostacyclin analogues show antifibrotic effects: fewer fibrocytes reach vascular remodeling sites, fibroblast activity is suppressed, and less collagen and fibronectin is produced and deposited.

“This is despite data demonstrating some antifibrotic properties of prostacyclin analogues through reduced fibrocyte recruitment to areas of vascular remodeling, suppression of fibroblast activity, and subsequent reduced production and deposition of collagen and fibronectin in in vivo models [117,118].”

• cites [117] sourceNot checked — no full text of the source
• cites [118] sourceNot checked — no full text of the source

May combine two claims.

In a phase 2 twelve-week trial of neramdomilast in IPF, without background antifibrotic therapy the median FVC change was 5.7 mL versus -81.7 mL for placebo, a difference of 88.4 mL; with concurrent antifibrotic use, neramdomilast improved FVC by 2.7 mL versus a reduction of 59.2 mL for placebo, a difference of 62.4 mL.

“Among those without background antifibrotic use, the median change in FVC with neramdomilast was 5.7 ml (95% CI −39.1 to 50.5) vs −81.7 ml (95% CI −133.5 to −44.8) in the placebo group, yielding a 88.4 ml (95% CI 29.5 to 154.2) difference. With concurrent antifibrotic use, neramdomilast improved FVC by 2.7 ml (95% CI −32.8 to 38.2) vs a reduction of 59.2 ml (95% CI −111.8 to −17.9) in placebo, for”

• cites [115] sourceNot checked — no full text of the source

May combine two claims.

TGF-beta is an important modulator of lung fibrosis that induces extracellular matrix production and precedes collagen formation and deposition.

“TGF-β is an exceptionally important modulator of lung fibrosis – it induces extracellular matrix production and precedes collagen formation and deposition [103].”

• cites [103] sourceNot checked — no full text of the source

May combine two claims.

In that taladegib trial, QLF fell by 9.4% in the experimental arm but rose by 1.1% in the placebo arm (P=0.047).

“Results demonstrated an improvement in percent predicted FVC of 1.9% in the ENV-101 arm versus a decline of 1.3% in the placebo group (P<0.05), along with a decrease in QLF by −9.4% in the experimental arm versus an increase of 1.1% in the placebo arm (P=0.047) [139].”

• cites [139]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

In a bleomycin-induced rat model of pulmonary fibrosis, C21 reduced both pulmonary hypertension and fibrosis.

“In the bleomycin-induced pulmonary fibrosis rat model, C21 has been shown to decrease pulmonary hypertension and pulmonary fibrosis [128].”

• cites [128] sourceNot checked — no full text of the source

May combine two claims.

ZSP1603 blocks the upregulation of TGF-β1, TIMP1, COL1A1, and α-SMA, showing protective and preventive effects against pulmonary fibrosis in bleomycin animal models.

“ZSP1603 inhibits the upregulation of TGF-β1, TIMP1, COL1A1, and α-SMA demonstrating protective and preventative effects against pulmonary fibrosis in bleomycin animal models of pulmonary fibrosis [169].”

• cites [169] sourceNot checked — no full text of the source

May combine two claims.

Preclinical stem cell studies have shown decreases in collagen deposition, matrix metalloproteinase activity, profibrotic and proinflammatory gene expression, lung fibrosis, and levels of TGF-β, IL-1β, IL-6, IL-10, Caspase-2, TNF-α, and IFN-λ.

“Preclinical studies have demonstrated reductions in collagen deposition, matrix metalloproteinase activity, profibrotic and proinflammatory gene expression, lung fibrosis, and TGF-β, IL-1β, IL-6, IL-10, Caspase-2, TNF-α, IFN-λ levels [156].”

• cites [156]Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

May combine two claims.

A phase 1 trial of 72 patients randomized to placebo or escalating SHR-1906 doses found the drug safe and well tolerated.

“A phase 1 trial consisting of 72 patients randomized to receive placebo versus various escalating doses of SHR-1906 demonstrated that it was safe and well tolerated [185].”

• cites [185] sourceNot checked — no full text of the source

May combine two claims.

TAS-115 is a multi-tyrosine kinase inhibitor that targets PDGFR, VEGFR, and CSF1-R and has shown antifibrotic effects in preclinical IPF animal models.

“TAS-115 is a multi-tyrosine kinase inhibitor with targets against PDGFR, VEGFR, and colony stimulating factor −1 receptor (CSF1-R), which demonstrated antifibrotic effects in preclinical animal models of IPF [193].”

• cites [193] sourceNot checked — no full text of the source

May combine two claims.

Bleomycin-induced pulmonary fibrosis proceeds in two steps: first, macrophages and polymorphonuclear leukocytes enter and release reactive oxygen species; second, extracellular matrix remodeling and collagen deposition occur.

“Bleomycin induced pulmonary fibrosis occurs in a two-step process: 1) the immediate phase consists of an influx of macrophages and polymorphonuclear leukocytes, which release reactive oxygen species, then 2) extracellular matrix remodeling and collagen deposition [180,181].”

• cites [180] sourceNot checked — no full text of the source
• cites [181] sourceNot checked — no full text of the source

May combine two claims.

Pamrevlumab, an anti-CTGF monoclonal antibody, had encouraging phase 2 IPF results, but its phase 3 trial did not show important improvements and the drug was abandoned for IPF.

“Despite very favorable phase 2 trials in IPF patients, its phase 3 trial failed to show important improvements and the drug was abandoned for IPF [71].”

• cites [71] sourceNot checked — no full text of the source

May combine two claims.

In a phase 2 tipelukast trial of 15 patients, three serious adverse events occurred, none judged related to the study drug by the principal investigator, and there was no benefit on key secondary efficacy endpoints: FVC, 6MWD, or mMRC.

“In 15 patients, there were three SAEs, but none related to the study drug per the principal investigator. There was no benefit in key secondary endpoints for efficacy: FVC, 6MWD, or modified Medical Research Dyspnea Scale (mMRC) (NCT02503657) [179].”

• cites [179] sourceNot checked — no full text of the source

May combine two claims.

Inflammatory cells and injured epithelial cells produce TNF-α along with IL-6, IL-1β, and TGF-β, and these cytokines activate fibroblast-to-myofibroblast conversion.

“TNF-α, along with several other proinflammatory cytokines including IL-6, IL-1β, and TGF-β, are produced by inflammatory cells and injured epithelial cells, which activate fibroblast to myofibroblast conversion [38].”

• cites [38] sourceNot checked — no full text of the source

May combine two claims.

Overexpressing extracellular superoxide dismutase reduced bleomycin-induced fibrosis, whereas superoxide dismutase-deficient mice showed a stronger fibrotic response.

“Overexpression of extracellular superoxide dismutase, a scavenger enzyme of reactive oxygen species superoxide anion, decreased resulting fibrosis from bleomycin exposure, while mice lacking superoxide dismutase had an increased fibrotic response [183].”

• cites [183] sourceNot checked — no full text of the source

May combine two claims.

In a phase 2 TAS-115 trial, 46 patients were divided into three cohorts-nintedanib, pirfenidone, and treatment-naive-and the results showed a slower rate of FVC decline.

“A phase 2 clinical trial divided 46 patients into 3 cohorts, those on nintedanib, those on pirfenidone, and those who were treatment naïve to both, with results demonstrating a decreased rate of decline in FVC [194].”

• cites [194] sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

A recent collaborative report advocated IPF trial endpoints reflecting patients' lived experience, proposing a composite endpoint with 'feels, functions, survives' measures that might include FVC.

“A recent collaborative report called for IPF trial endpoints that mirror the “lived experiences of patients with IPF perhaps” by creating a composite endpoint that incorporates “feels, functions, survives” measures that could include the FVC as a component [195].”

• cites [195] sourceNot checked — no full text of the source